Related Experiment Video
Updated: Apr 7, 2026
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
Guillain-Barré syndrome
Benjamin R Wakerley1, Nobuhiro Yuki
1Department of Neurology, Gloucestershire Royal Hospital, Gloucester, UK.
Guillain-Barré syndrome, a cause of paralysis, involves Campylobacter jejuni triggering an immune response. Novel therapies targeting the complement cascade, like eculizumab, show promise in preventing nerve damage.
Area of Science:
- Neuroimmunology
- Pathogenesis of Neurological Disorders
- Therapeutic Development
Background:
- Guillain-Barré syndrome is the leading cause of acute flaccid paralysis globally.
- Pathogenesis involves Campylobacter jejuni triggering antibody-mediated neuropathy via molecular mimicry.
- Current research focuses on understanding nerve damage mechanisms.
Discussion:
- Antibody cross-reactivity with peripheral nerve gangliosides is a key factor.
- Novel therapies aim to inhibit the complement cascade, specifically the membrane attack complex.
- Eculizumab, a monoclonal antibody, blocks C5a and C5b-9 formation.
Key Insights:
- Eculizumab demonstrates efficacy in preventing antiganglioside antibody-induced neuropathy in vitro and in mouse models.
- Targeting the complement cascade offers a promising therapeutic strategy.
- Understanding molecular mechanisms drives innovative treatment development.
Outlook:
- Eculizumab is currently in Phase II clinical trials for Guillain-Barré syndrome.
- Further research may refine complement-targeted therapies for autoimmune neuropathies.
- Advancements in understanding pathogenesis are crucial for future treatment strategies.
More Related Videos
09:29Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
08:16Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...